Scarica l'app Stockscreener
3.19
4.59%
0.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.05
Aprire:
$3.06
Volume 24 ore:
1.75M
Relative Volume:
0.93
Capitalizzazione di mercato:
$305.12M
Reddito:
$829.00M
Utile/perdita netta:
$-399.90M
Rapporto P/E:
-0.7391
EPS:
-4.3159
Flusso di cassa netto:
$-23.20M
1 W Prestazione:
+11.15%
1M Prestazione:
-43.14%
6M Prestazione:
-33.26%
1 anno Prestazione:
-45.84%
Intervallo 1D:
$3.01
$3.21
Intervallo di 1 settimana:
$2.9225
$3.295
Portata 52W:
$2.74
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
Nome
Myriad Genetics Inc
Settore
Industria
Telefono
801-584-3600
Indirizzo
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, NTRA, A, IDXX
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
3.19 | 307.99M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
628.15 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.97 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
336.71 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
154.77 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
IDXX
Idexx Laboratories Inc
|
550.01 | 43.00B | 4.45B | 1.10B | 1.06B | 13.59 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-21 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-12 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Iniziato | Craig Hallum | Buy |
| 2024-12-10 | Iniziato | UBS | Neutral |
| 2024-12-09 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Underperform |
| 2024-05-08 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Ripresa | Piper Sandler | Neutral |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Underweight |
| 2023-05-23 | Aggiornamento | Goldman | Sell → Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Iniziato | Stephens | Equal-Weight |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Sell |
| 2019-09-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Downgrade | Needham | Strong Buy → Hold |
| 2019-07-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-03-12 | Reiterato | Needham | Strong Buy |
| 2019-01-03 | Iniziato | Needham | Strong Buy |
| 2018-11-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Iniziato | Goldman | Sell |
| 2018-01-22 | Reiterato | Barclays | Equal Weight |
| 2018-01-05 | Iniziato | BTIG Research | Buy |
| 2017-10-02 | Ripresa | Leerink Partners | Mkt Perform |
| 2017-08-09 | Reiterato | Barclays | Equal Weight |
| 2017-02-08 | Aggiornamento | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Iniziato | Deutsche Bank | Sell |
| 2016-10-10 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
Mostra tutto
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect - ACCESS Newswire
Burning Rock and Myriad Announce Global Strategic Technology Lice - The National Law Review
MYGN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Myriad Genetics Inc. - accessnewswire.com
MYGN Maintained by Stephens & Co. -- Price Target Lowered to $3. - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Marquis Who's Who Honors Ben Wheeler for Expertise in Finance and Healthcare - 24-7 Press Release Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Myriad Genetics (MYGN): Glenview Capital and Larry Robbins report exit from stake - Stock Titan
Myriad Genetics (MYGN): Vestal Point Capital discloses 6.1% stake in 13G filing - Stock Titan
Myriad Genetics Faces Multiple Investor Investigations - stl.news
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Assenagon Asset Management S.A. Reduces Holdings in Myriad Genetics, Inc. $MYGN - MarketBeat
3 Healthcare Stocks with Open Questions - Yahoo Finance
Price-Driven Insight from (MYGN) for Rule-Based Strategy - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, In - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out - ACCESS Newswire
Myriad Genetics (MYGN) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Myriad Genetics And 2 Other Promising Penny Stocks For Your Watchlist - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Connect - accessnewswire.com
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law - FinancialContent
Myriad Genetics (NASDAQ:MYGN) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Myriad Genetics Inc (MYD.HA) stock price, news, quote and history - Yahoo Finance Australia
State Street Corporation (NYSE: STT) discloses 5.3% holding in Myriad Genetics - Stock Titan
Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating Through a Challenging Landscape with 69.36% Potential Upside - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Myriad Genetics (MYGN) - globenewswire.com
Myriad Genetics (NASDAQ:MYGN) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP - GlobeNewswire
MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN) - Business Wire
MYGN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Myriad Genetics - Morningstar
Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel - GlobeNewswire
Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $5.34, Implies 87% Upside - TradingView
Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN) - PR Newswire
MYGN Slides As Myriad Genetics Slashes 2026 Revenue Outlook - timothysykes.com
Myriad Genetics (MYGN) Missed Q2 And Cut Guidance, Is It Still 54% Below Fair Value? - Yahoo Finance
MYGN Stock Slides As Myriad Genetics Slashes 2026 Outlook - timothysykes.com
Myriad Genetics: Strong Oncology Demand, But Monetization Breaks Down (NASDAQ:MYGN) - Seeking Alpha
Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $5.75, Implies 7% Upside - TradingView
Myriad Genetics (NASDAQ:MYGN) Posts Earnings Results, Misses Estimates By $0.22 EPS - MarketBeat
MYRIAD GENETICS ($MYGN) Releases Q2 2026 Earnings - Quiver Quantitative
Myriad: Q2 Earnings Snapshot - KVUE
Wells Fargo Maintains Myriad Genetics(MYGN.US) With Hold Rating, Maintains Target Price $5.5 - Moomoo
Myriad Genetics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Myriad Genetics (MYGN) Reports Q2: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Myriad Genetics rebuilt its AI platform after costs ballooned. Now, it can process documents in seconds. - Business Insider
Myriad Genetics Inc (MYGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Myriad Genetics Inc Azioni (MYGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
0.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):